atai Life Sciences to Participate in September Investor Events

Articles | September 7, 2022

NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor conferences in September: Citi’s 17th Annual BioPharma Conference in Boston Format: Industry Panel… Read More

atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update

Articles | August 15, 2022

– Added an anticipated additional year of runway into 2025 through securing non-dilutive debt facility from Hercules combined with execution of cost optimizations by prioritizing atai’s development programs with anticipated meaningful near-term clinical value inflections – Key achieved R&D milestones include completion of the clinical phase of the Drug-Drug-Interaction (DDI)… Read More

atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital

Articles | August 15, 2022

– Non-dilutive financing facility, plus $312M existing cash on hand as of June 30, 2022, gives atai access to up to $487M to continue developing next generation mental health treatments – Flexible draw availability provides optionality to optimize liquidity and capital structure moving forward NEW YORK and BERLIN, Aug. Read More

atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update

Articles | August 1, 2022

atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update NEW YORK and BERLIN, Aug. 01, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its second quarter 2022… Read More

atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer

Articles | June 30, 2022

June 30, 2022 Dr. Chad Beyer will join as CEO on July 1, 2022   NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) — Kures Therapeutics, Inc (“Kures”), an atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”) company focused on developing treatment options to better manage addictions, depression, and pain, today announced… Read More

Stephen Bardin to Join atai Life Sciences as CFO Designate

News | June 17, 2022

Stephen Bardin to Join atai Life Sciences as CFO Designate June 17, 2022 Stephen Bardin will join as CFO Designate on June 27, 2022 After a transition period, atai’s current CFO Greg Weaver will be moving into a part time strategic advisory role NEW YORK and BERLIN, June… Read More